Alexis Borisy

EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

Near­ly a year in­to its mis­sion of rewrit­ing the rules of drug pric­ing, EQRx has made a few key late-stage pick­ups to speed up its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA